Clinical Trials Logo
  1. Home
  2. Cirrhosis
  3. NCT04915573
  4. Details
NCT04915573 Clinical Trial

Antimicrobial Resistance in Cirrhotic Patients

Cirrhosis Clinical Trial

Official title:
Antimicrobial Resistance Among Sputum Pathogens in Post Hepatitis Cirrhotic Patients

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT04915573
Other study ID # 34647/4/21
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 7, 2021
Est. completion date September 2021

Study information
Verified date June 2021
Source Mansoura University
Contact Noha Mansour, Ph.D
Phone 0020403315352
Email dr.nohamansour@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Cirrhotic patients are more vulnerable to bacterial infection, and infection is one of the most common causes of acute liver disease decompensation.

Description:

Cirrhotic patients are more vulnerable to bacterial infection which is a common cause of acute liver disease decompensation. The aim of this study will characterize the antimicrobial resistance and distribution of bacteria isolated from chronic hepatic patients with pulmonary infections, as well as to evaluate the antimicrobial susceptibility of bacteria isolated from sputum.

Recruitment information / eligibility
Status Recruiting
Enrollment 100
Est. completion date September 2021
Est. primary completion date September 2021
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Adults' older than 18 years with clinical evidence of liver disease Exclusion Criteria: 1. Pregnancy 2. Intensive care unite stay of more than 24 hours 3. Malignancy 4. Organ transplantation 5. Acquired immune deficiency syndrome

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• Specimen
Sputum will be collected in clean disposable containers

Locations
Country Name City State
Egypt Tanta University Hospitals Tanta

Sponsors (2)
Lead Sponsor Collaborator
Mansoura University Tanta University

Country where clinical trial is conducted

Egypt, 

Outcome
Type Measure Description Time frame Safety issue
Primary Isolate Identification Distribution of bacterial isolates from sputum of cirrhotic patients expressed by frequency of each isolate One day
Primary Antimicrobial resistance Antimicrobial susceptibility testing to antibiotics determined by kirby-bauer disk diffusion One day
See also
  Status Clinical Trial Phase
Completed NCT01884415 - Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis Phase 3
Recruiting NCT05014594 - Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT Phase 2
Not yet recruiting NCT03631147 - The Effect of Rifaximin on Portal Vein Thrombosis N/A
Completed NCT04939350 - Evaluation of the Vaccination Coverage of Cirrhotic Patients Followed in the General Hospitals in France in 2021
Completed NCT02528760 - To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis N/A
Recruiting NCT05484206 - Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 Phase 1
Not yet recruiting NCT05538546 - Baveno VI Criteria in Dynamic Monitoring of High-risk Varices in Compensated Cirrhotic Patients
Not yet recruiting NCT04053231 - Hepatocarcinoma Recurrence on the Liver Study - Part2
Recruiting NCT02983968 - Use of the French Healthcare Insurance Database
Completed NCT02705534 - Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1 Phase 3
Completed NCT02596880 - Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics Phase 3
Completed NCT02247414 - Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection Phase 4
Completed NCT02016196 - Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS Phase 3
Withdrawn NCT01956864 - Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer Phase 1
Completed NCT01447537 - Mechanisms Involved in the Benefits of an Exercise Programme in Patients With Cirrhosis N/A
Completed NCT01362855 - Advance Care Planning Evaluation in Hospitalized Elderly Patients
Completed NCT02113631 - Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir N/A
Active, not recruiting NCT01205074 - ¹³C-Methacetin Breath Test (MBT) Methodology Study Phase 2/Phase 3
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Completed NCT01231828 - Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies. N/A